Study S002287

A Cohort Study of the Benefits of Bydureon in Customary Clinical Care in the United States - Additional Analyses

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02917057
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 6024
Start: 2015-08-01
Primary completion: 2015-08-01
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide once weekly; DRUG:basal insulin
Results posted: FALSE

Registered primary outcomes

Changes from baseline in HbA1c (%) [one year post-index]
Changes from baseline in weight (kg) [one year post-index]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026152	Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States. Loughlin AM, Diabetes, obesity & metabolism	2018	Nonrandomized study	PMID 29193561 DOI	registry reference BACKGROUND:29193561